From the BMY earnings call last week:Thomas J. Lynch, Bristol-Myers Squibb Company - Executive VP of R&D & Chief Scientific Officer [41]
-------------------------------------------------------------------------------
**********
"Next is Nektar. There are 3 validated I-O mechanisms that have been shown to improve survival in cancer, PD-1, CTLA-4, IL-2. Bristol-Myers now has all 3 of these in clinical development, and we could not be more proud of our relationship with Nektar and very eager to see what that data continues to evolve."
The Diab oral abstract should be interesting, although I am not sure how much data will be available from the P2 expansion phase. If I recall correctly, the 2 substantial increases in the P2 expansion cohorts occurred in November -- to 240 -- and in February -- to 330, and it will take time to enroll and then treat new patients generating data from the 3-week cycles over which the combo is administered. I would be surprised if the P2 portion of the trial wrapped up by year end. The October 2018 completion estimate in CT.gov needs to be updated to, IMO, mid-2019.
Also, there will be no results data from the Propel trial regarding the efficacy of the 214 combos with Keytruda and Tecentriq. That trial is a "Trial in Progress" (designated as TPS in the abstract title), and the links below make it clear that TPS trials are prohibited from including any results data.